Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension.

Literature DB >> 23031155

Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension.

Joel Handler¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2012 PMID： 23031155 PMCID： PMC8108764 DOI： 10.1111/j.1751-7176.2012.00693.x

Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN： 1524-6175 Impact factor: 3.738

× No keyword cloud information.

16 in total

Review 1. Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension.

Authors: S A R Doi; S Abalkhail; M M Al-Qudhaiby; K Al-Humood; M F Hafez; K A S Al-Shoumer
Journal: J Hum Hypertens Date: 2006-04-13 Impact factor: 3.012

2. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors: Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal: Lancet Date: 2008-06-07 Impact factor: 79.321

Review 3. Primary aldosteronism: diagnosis and treatment.

Authors: W F Young; M J Hogan; G G Klee; C S Grant; J A van Heerden
Journal: Mayo Clin Proc Date: 1990-01 Impact factor: 7.616

4. Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Authors: Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal: Hypertension Date: 2007-02-19 Impact factor: 10.190

5. Medical management of aldosterone-producing adenomas.

Authors: R P Ghose; P M Hall; E L Bravo
Journal: Ann Intern Med Date: 1999-07-20 Impact factor: 25.391

6. Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors: Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal: Am J Hypertens Date: 2003-11 Impact factor: 2.689

7. Efficacy and tolerance of spironolactone in essential hypertension.

Authors: X Jeunemaitre; G Chatellier; C Kreft-Jais; A Charru; C DeVries; P F Plouin; P Corvol; J Menard
Journal: Am J Cardiol Date: 1987-10-01 Impact factor: 2.778

8. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.

Authors: E Born-Frontsberg; M Reincke; L C Rump; S Hahner; S Diederich; R Lorenz; B Allolio; J Seufert; C Schirpenbach; F Beuschlein; M Bidlingmaier; S Endres; M Quinkler
Journal: J Clin Endocrinol Metab Date: 2009-02-03 Impact factor: 5.958

Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension.

Review 1. Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension.

2. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Review 3. Primary aldosteronism: diagnosis and treatment.

4. Effect of spironolactone on blood pressure in subjects with resistant hypertension.

5. Medical management of aldosterone-producing adenomas.

6. Efficacy of low-dose spironolactone in subjects with resistant hypertension.

7. Efficacy and tolerance of spironolactone in essential hypertension.

8. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.

Review 9. Primary aldosteronism: a practical approach to diagnosis and treatment.

Review 10. Primary aldosteronism: diagnosis and treatment.

Review 1. Assessment and management of resistant hypertension.

Review 2. Management of hypertension in primary aldosteronism.

3. Commentary in support of a highly effective hypertension treatment algorithm.